Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAIRI-Guided Adjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT07590024Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2026
- Primary completion
- Dec 2030
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started May 2026; status: recruiting.
02
Drugs
capecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07590024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07590024.